Advisory Alpha LLC Grows Stock Holdings in Vertex Pharmaceuticals Incorporated $VRTX

Advisory Alpha LLC raised its position in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 12.4% during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,701 shares of the pharmaceutical company’s stock after purchasing an additional 187 shares during the period. Advisory Alpha LLC’s holdings in Vertex Pharmaceuticals were worth $757,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in the company. Activest Wealth Management purchased a new position in shares of Vertex Pharmaceuticals in the first quarter worth about $25,000. Clal Insurance Enterprises Holdings Ltd increased its holdings in shares of Vertex Pharmaceuticals by 450.0% in the first quarter. Clal Insurance Enterprises Holdings Ltd now owns 55 shares of the pharmaceutical company’s stock worth $27,000 after buying an additional 45 shares during the period. Flaharty Asset Management LLC purchased a new position in shares of Vertex Pharmaceuticals in the first quarter worth about $32,000. American National Bank & Trust increased its holdings in shares of Vertex Pharmaceuticals by 515.4% in the second quarter. American National Bank & Trust now owns 80 shares of the pharmaceutical company’s stock worth $36,000 after buying an additional 67 shares during the period. Finally, Solstein Capital LLC purchased a new position in shares of Vertex Pharmaceuticals in the second quarter worth about $40,000. Hedge funds and other institutional investors own 90.96% of the company’s stock.

Vertex Pharmaceuticals Price Performance

Shares of NASDAQ:VRTX opened at $422.39 on Wednesday. Vertex Pharmaceuticals Incorporated has a 1 year low of $362.50 and a 1 year high of $519.88. The company has a market cap of $108.30 billion, a PE ratio of 30.19 and a beta of 0.43. The stock’s 50-day moving average is $400.19 and its 200 day moving average is $433.48.

Vertex Pharmaceuticals (NASDAQ:VRTX) last announced its quarterly earnings results on Monday, August 4th. The pharmaceutical company reported $4.52 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $4.24 by $0.28. Vertex Pharmaceuticals had a return on equity of 23.91% and a net margin of 31.86%.The company had revenue of $2.94 billion for the quarter, compared to the consensus estimate of $2.90 billion. During the same quarter in the previous year, the business earned ($12.83) EPS. Vertex Pharmaceuticals’s revenue was up 11.3% compared to the same quarter last year. Vertex Pharmaceuticals has set its FY 2025 guidance at EPS. Analysts expect that Vertex Pharmaceuticals Incorporated will post 15.63 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research analysts have recently commented on VRTX shares. Wells Fargo & Company upgraded Vertex Pharmaceuticals from an “equal weight” rating to an “overweight” rating and set a $460.00 price objective on the stock in a report on Wednesday, August 6th. Stifel Nicolaus decreased their price objective on Vertex Pharmaceuticals from $494.00 to $455.00 and set a “hold” rating on the stock in a report on Tuesday, August 5th. Truist Financial set a $490.00 price objective on Vertex Pharmaceuticals and gave the stock a “buy” rating in a report on Tuesday, August 5th. Guggenheim reduced their price target on Vertex Pharmaceuticals from $558.00 to $546.00 and set a “buy” rating on the stock in a report on Wednesday, August 6th. Finally, Leerink Partners upgraded Vertex Pharmaceuticals from a “market perform” rating to an “outperform” rating and reduced their price target for the company from $458.00 to $456.00 in a report on Thursday, September 25th. One investment analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and twelve have given a Hold rating to the company’s stock. According to data from MarketBeat.com, Vertex Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average price target of $494.38.

Insiders Place Their Bets

In other news, Director Bruce I. Sachs acquired 5,000 shares of the business’s stock in a transaction on Wednesday, August 6th. The shares were acquired at an average cost of $389.68 per share, with a total value of $1,948,400.00. Following the transaction, the director owned 45,000 shares in the company, valued at $17,535,600. The trade was a 12.50% increase in their position. The acquisition was disclosed in a filing with the SEC, which can be accessed through this link. Insiders own 0.20% of the company’s stock.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.